Salt and crystal form of steroid derivative regulator
AssigneesShanghai Hansoh Biomedical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
InventorsZongbin Li, Yuanzhuo Kuang, Linsong Guo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABAA receptor regulator in treatment of depression, convulsions, Parkinsonism and nervous system diseases.
Claims14
A crystal form of formula (VI), having the following structure:
- wherein x is 0, the crystal form is crystal form I of free base, the X-ray powder diffraction pattern thereof has any 3 to 11 of the diffraction peaks at 2θ (±0.2°) of 16.7, 12.6, 17.4, 7.3, 20.2, 20.6, 11.9, 11.1, 23.9, 21.9 and 38
- or,
- wherein x is 0, the crystal form is crystal form II of free base, the X-ray powder diffraction pattern thereof has diffraction peaks at 2θ (±0.2°) of 11.7, 13.4, 13.6, 16.6 and 18.9;
- or,
- wherein x is 0, the crystal form is crystal form III of free base, the X-ray powder diffraction pattern thereof has diffraction peaks at 2θ (±0.2°) of 10.0, 11.7, 13.7, 16.6, 18.9 and 19.2:
- or,
- wherein M is methanesulfonic acid, x is 1, the X-ray powder diffraction pattern thereof has diffraction peaks at 2θ (±0.2°) of 12.5, 13.5, 194 and 19.9.
A crystal form of a compound of formula (VI), having the following structure,
- wherein
- x is 0, the crystal form is crystal form I of free base and the X-ray powder diffraction pattern thereof has diffraction peaks at 2θ (±0.2°) of 16.7, 12.6 and 14.6;
- the crystal form I of free base has diffraction peaks at 2θ (±0.2°) of 7.3, 13.2, 17.4, 19.4, 20.2 and 20.6;
- or
- the crystal form I of free base has diffraction peaks at 2θ (±0.2°) of 9.2, 11.1, 11.9, 19.6, 22.3 and 25.5.
Dependencies are inferred from the claim text.